Friday, September 14, 2018
1310 Longworth House Office Building
Committee on House Administration Hearing Room
On August 31, President Trump notified Congress of his intent to sign a trade agreement with Mexico. This agreement could have a significant impact on the United States’ economy, including prescription drug pricing and the emerging biosimilars market.
Please join the Association for Accessible Medicines (AAM) for a briefing to discuss the proposed NAFTA agreement, its impact on rising prescription drug prices and recommendations for a stronger agreement.
Jeff Francer (Moderator)
Senior Vice President and General Counsel, Association for Accessible Medicines
Marcie McClintic Coates
Head of Global Policy, Mylan
President and Founder, Patients for Affordable Drugs
Director, Health Services Research, AARP
This briefing has been designed to comply with House and Senate ethics rules. Lunch will be provided.
To RSVP, contact Lindsey Novak